Drug Combination Details
| General Information of the Combination (ID: C97109) | |||||
|---|---|---|---|---|---|
| Name | Acarbose NP Info | + | Cyclosporin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Plaque psoriasis
[ICD-11: EA90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL17 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL22 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL23 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male BALB/c mice aged 6 weeks were used in this study. | |||||
| Experimental
Result(s) |
Acar and low-dose CsA in combination alleviates psoriatic skin lesions by inhibiting inflammation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice. Molecules. 2020 Apr 16;25(8):1822. | |||
